Diabetes complications and comorbidities: Hyperglycemia

A proof-of-concept study indicates that taking some basal insulin as a single injection of degludec improves glucose control during and after exercise in people with type 1 diabetes who prefer to remove their insulin pump while exercising.

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.

Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Oriot P et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1170-7

Sanjay Kalra and Silver Bahendeka, East Africa Diabetes Study Group Chair, provide an overview of the latest insulin guidance developed to aid management in a challenging region, facing familiar struggles.

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

Song R, Cao S. Diabetes Ther 2018; 9: 1377. doi: 10.1007/s13300-018-0417-1

As the utility and availability of devices surges, so too do patient expectations. Advisory Board member Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.

Dickens LT, Naylor RN. Curr Diab Rep 2018; 18: 12. doi: 10.1007/s11892-018-0982-8

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

Ovsyannikova AK et al. Diabetes Ther 2018; 9: 413. doi: 10.1007/s13300-017-0350-8

Editorial Board member Sanjay Kalra shares his pragmatic and practical suggestions on initiating, monitoring, and titrating suitable patients on U500 regular insulin.

Advisory Board member and pharmacist, Josh Neumiller, presents a practical guide to support clinical decision-making in the initiation and titration of U300 insulin glargine and insulin degludec.

Romano F et al. Acta Diabetol 2017; 54: 1139. doi: 10.1007/s00592-017-1057-z

van Megen KM et al. Diabetologia 2017; 60: 2252. doi: 10.1007/s00125-017-4403-3

Tully C et al. Curr Diab Rep 2016; 16: 85. doi: 10.1007/s11892-016-0779-6